Author

C. D. Weiss

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 7 Approach:experimental assay· 6 Organism:human· 5 Assay:proteomics· 3 Organism:virus· 2 Assay:spatial transcriptomics· 1 Approach:statistical model· 1

Frequent Co-Authors

R. Vassell· 7 shared W. Wang· 7 shared S. Lusvarghi· 6 shared S. N. Neerukonda· 6 shared R. Wang· 4 shared A. E. Eakin· 3 shared K. J. Erlandson· 3 shared L. C. Katzelnick· 3 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

R. Vassell

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

D614G and Omicron SARS-CoV-2 variant spike proteins differ in the effects of N-glycan modifications on spike expression, virus infectivity, and neutralization by some therapeutic antibodies

S. Lusvarghi, C. B. Stauft, R. Vassell, B. Williams, H. Baha, W. Wang, S. N. Neerukonda, T. Wang, C. D. Weiss

This study compares how N-glycan modifications affect spike expression, infectivity, and antibody neutralization in SARS-CoV-2 D614G and Omicron variants.

bioRxiv · May 10, 2023 · PreprintMicrobiology

Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

W. Wang, S. Lusvarghi, R. Subramanian, E. Nusrat, R. Wang, E. Goguet, A. Fries, F. Echegaray, R. Vassell, S. Coggins, S. Richard, D. Lindholm, K. Mende, E. Ewers, D. Larson, , C. D. Weiss

The paper compares antibody responses to different SARS-CoV-2 variants after vaccination and infection, finding that post-vaccination Omicron infection induces broader immunity than triple vaccination alone.

bioRxiv · Jul 5, 2022Microbiology

Characterization of entry pathways, species-specific ACE2 residues determining entry, and antibody neutralization evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 variants

S. N. Neerukonda, R. Wang, R. Vassell, H. Baha, S. Lusvarghi, S. Liu, T. Wang, C. D. Weiss, W. Wang

This study characterizes the entry mechanisms and antibody neutralization resistance of Omicron variants BA.1, BA.1.1, BA.2, and BA.3 compared to the D614G strain.

bioRxiv · Jun 1, 2022 · PreprintMicrobiology

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster

S. Lusvarghi, S. D. Pollett, S. N. Neerukonda, W. Wang, R. Wang, R. Vassell, N. J. Epsi, A. C. Fries, B. K. Agan, D. A. Lindholm, C. J. Colombo, R. Mody, E. C. Ewers, T. Lalani, A. Ganesan, , C. D. Weiss

A third dose of Pfizer/BioNTech vaccine significantly boosts Omicron neutralizing antibodies, while convalescent sera and therapeutic antibodies show variable and often low neutralization.

bioRxiv · Dec 22, 2021Microbiology

SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity

S. N. Neerukonda, R. Vassell, S. Lusvarghi, R. Wang, F. Echegaray, L. Bentley, A. E. Eakin, K. J. Erlandson, L. C. Katzelnick, C. D. Weiss, W. Wang

This study evaluates the neutralization resistance and spike protein properties of SARS-CoV-2 B.1.617 variants, finding modest resistance to sera and therapeutic antibodies, but enhanced cleavage and fusogenic activity in Delta variants.

bioRxiv · Nov 5, 2021Microbiology

Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects

S. Lusvarghi, W. Wang, R. Herrup, S. N. Neerukonda, R. Vassell, L. Bentley, A. E. Eakin, K. J. Erlandson, C. D. Weiss

The paper evaluates resistance of 25 therapeutic antibodies to SARS-CoV-2 variants with multiple spike substitutions, finding key substitutions predict resistance but other substitutions can modify it unpredictably.

bioRxiv · Jul 16, 2021Microbiology

Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2

S. N. Neerukonda, R. Vassell, R. Herrup, S. Liu, T. Wang, K. Takeda, Y. Yang, T.-L. Lin, W. Wang, C. D. Weiss

The paper establishes a SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells expressing ACE2 and TMPRSS2, showing good correlation with other assays.

bioRxiv · Dec 26, 2020Microbiology